Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
Last trade$9.11
Day change-$0.045 (-0.49%)
Day range$8.89 – $9.26
Volume75,747
Market cap$347M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$346.72M
Price / earnings
22.19×
Price / book
2.31×
Price / sales
1.12×
EV / sales
1.1×
EV / EBITDA
6.11×
Profitability
Earnings per share
$0.41
Return on assets
7.52%
Return on equity
10.41%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
1.25×
Quick ratio
1.16×
Cash ratio
0.2×
Cash flow
Price / cash flow
6.43×
Price / free cash flow
16.22×
Free cash flow
$21.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$80.67M
$78.1M
$75.41M
$76.18M
$71.91M
$63.06M
$59.13M
$60.7M
Cost of revenue
$34.48M
$33.05M
$32.59M
$32.08M
$30.57M
$26.33M
$25.85M
$24.56M
Gross profit
$46.19M
$45.05M
$42.83M
$44.1M
$41.35M
$36.73M
$33.28M
$36.14M
Selling, general and administrative
$35.51M
$39.16M
$37.24M
$34.52M
$31.92M
$31.14M
$30.74M
$29.73M
Research and development
$501K
$504K
$579K
$598K
$775K
$847K
$797K
$803K
Total operating expenses
$38.88M
$40.06M
$38.21M
$35.5M
$35.27M
$32.34M
$31.88M
$30.88M
Operating income
$7.32M
$4.99M
$4.62M
$8.6M
$6.07M
$4.39M
$1.4M
$5.26M
Interest expense
-$177K
-$248K
-$305K
$0
-$507K
-$132K
-$179K
$0
Income before taxes
$6.79M
$4.05M
$3.99M
$8.01M
$5.14M
$4.96M
$3.66M
$6.31M
Income taxes
$2.05M
$1.15M
$1.28M
$2.19M
$1.54M
$1.71M
$952K
$1.88M
Net income
$4.74M
$2.9M
$2.71M
$5.82M
$3.6M
$3.25M
$2.71M
$4.42M
Net income attributable to common shareholders
$4.64M
$2.76M
$2.58M
$5.64M
$3.51M
$3.16M
$2.63M
$4.32M
EBITDA
$15.03M
$12.51M
$12.24M
$16.17M
$13.61M
$11.28M
$8.01M
$11.63M
Basic earnings per share
$0.12
$0.07
$0.07
$0.15
$0.09
$0.08
$0.07
$0.11
Diluted earnings per share
$0.11
$0.07
$0.06
$0.14
$0.09
$0.08
$0.06
$0.10
Recent news
Company coverage with links to the original publishers.
CeriBell, Inc. (CBLL) reported a quarterly loss of $0.48 per share, beating consensus estimates of $0.50 loss, with revenues of $29.34 million exceeding expectations by 0.70%. However, losses widened year-over-year from $0.37 to $0.48 per share. The stock has gained 22.9% year-to-date but carries a Zacks Rank #3 (Hold) rating, with the Medical-Products industry ranking in the bottom 35% of sectors.
Boston Scientific reported Q3 2026 earnings of $0.73 per share, matching consensus estimates, with revenues of $5.14 billion slightly exceeding expectations. However, the stock has underperformed significantly, down 52.7% year-to-date versus the S&P 500's 12.8% gain. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, and its industry (Medical - Products) ranks in the bottom 34% of sectors.
Viemed Healthcare (VMD) is drawing attention from options traders due to high implied volatility in its November 2026 $5.00 call options, suggesting market expectations for significant price movement. However, the company maintains a Zacks Rank #3 (Hold) rating, and analyst consensus estimates for the upcoming quarter have declined slightly from 13 cents to 12 cents per share over the last 60 days. The elevated implied volatility may present opportunities for premium-selling strategies rather than directional bets.
Viemed Healthcare, a leading provider of respiratory care and home medical equipment services, reported record financial results for the fourth quarter and full year 2024, with strong growth in revenue, net income, and patient counts. The company also provided guidance for 2025, expecting continued growth in revenue and adjusted EBITDA.
Viemed Healthcare, Inc. announced that it will host its Quarterly Conference Call on Thursday, August 8, 2024 at 11:00 a.m. ET. The company is a national leader in respiratory care and technology-enabled home medical equipment services.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.